{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2024:3JJY3DNXYFSGREG4AHI2KG7ABW","short_pith_number":"pith:3JJY3DNX","canonical_record":{"source":{"id":"2408.17392","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2024-08-30T16:28:29Z","cross_cats_sorted":[],"title_canon_sha256":"59e589e5697516c0aa6a246e12849efb7fd4b9facfa7986581dc9353d8ad6f0e","abstract_canon_sha256":"fff41535525e3ea669295937af001f3c8d4fb7d18159f69bd513026cefd5b307"},"schema_version":"1.0"},"canonical_sha256":"da538d8db7c1646890dc01d1a51be00d911057d221d039b97682c6a34951b72c","source":{"kind":"arxiv","id":"2408.17392","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2408.17392","created_at":"2026-07-05T09:01:14Z"},{"alias_kind":"arxiv_version","alias_value":"2408.17392v1","created_at":"2026-07-05T09:01:14Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2408.17392","created_at":"2026-07-05T09:01:14Z"},{"alias_kind":"pith_short_12","alias_value":"3JJY3DNXYFSG","created_at":"2026-07-05T09:01:14Z"},{"alias_kind":"pith_short_16","alias_value":"3JJY3DNXYFSGREG4","created_at":"2026-07-05T09:01:14Z"},{"alias_kind":"pith_short_8","alias_value":"3JJY3DNX","created_at":"2026-07-05T09:01:14Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2024:3JJY3DNXYFSGREG4AHI2KG7ABW","target":"record","payload":{"canonical_record":{"source":{"id":"2408.17392","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2024-08-30T16:28:29Z","cross_cats_sorted":[],"title_canon_sha256":"59e589e5697516c0aa6a246e12849efb7fd4b9facfa7986581dc9353d8ad6f0e","abstract_canon_sha256":"fff41535525e3ea669295937af001f3c8d4fb7d18159f69bd513026cefd5b307"},"schema_version":"1.0"},"canonical_sha256":"da538d8db7c1646890dc01d1a51be00d911057d221d039b97682c6a34951b72c","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T09:01:14.770622Z","signature_b64":"MswdP5WyqinALhugN40moC+fQ+IdA070hXZrKjtaJZTGIrasaBhiiFNGTzKE6Z2xEMaEIolB76LsN+Z+2KbLAA==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"da538d8db7c1646890dc01d1a51be00d911057d221d039b97682c6a34951b72c","last_reissued_at":"2026-07-05T09:01:14.770281Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T09:01:14.770281Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"2408.17392","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T09:01:14Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"JDmgDW0PviyyImz6ZFsDKFpDRCprr1Ci3W9z0cLNNPxuftaDlGlIzGKnL/iEhsFGQGHN9btl39zHXc8E1zuQDQ==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-07-12T08:47:08.412677Z"},"content_sha256":"74adf5d478e147da4e8ea63b500f1dad53858fc1eceac180f5e8c1666c7ee980","schema_version":"1.0","event_id":"sha256:74adf5d478e147da4e8ea63b500f1dad53858fc1eceac180f5e8c1666c7ee980"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2024:3JJY3DNXYFSGREG4AHI2KG7ABW","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Dual-criterion Dose Finding Designs Based on Dose-Limiting Toxicity and Tolerability","license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Ying Yuan, Yunlong Yang","submitted_at":"2024-08-30T16:28:29Z","abstract_excerpt":"The primary objective of Phase I oncology trials is to assess the safety and tolerability of novel therapeutics. Conventional dose escalation methods identify the maximum tolerated dose (MTD) based on dose-limiting toxicity (DLT). However, as cancer therapies have evolved from chemotherapy to targeted therapies, these traditional methods have become problematic. Many targeted therapies rarely produce DLT and are administered over multiple cycles, potentially resulting in the accumulation of lower-grade toxicities, which can lead to intolerance, such as dose reduction or interruption. To addres"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2408.17392","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2408.17392/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T09:01:14Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"Sjm/bgwztoUIjVZm+3P/Zp7cTp2Gg1nDkY/6lwmfgPfsEGk7893FkcPrbHYGQxgMEXDMP61WJte7CmymxfjmDQ==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-07-12T08:47:08.413043Z"},"content_sha256":"584d0a67c7a8b0f15b03501ce4406fe417bbf5d50802d12cba5c8397917356de","schema_version":"1.0","event_id":"sha256:584d0a67c7a8b0f15b03501ce4406fe417bbf5d50802d12cba5c8397917356de"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/3JJY3DNXYFSGREG4AHI2KG7ABW/bundle.json","state_url":"https://pith.science/pith/3JJY3DNXYFSGREG4AHI2KG7ABW/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/3JJY3DNXYFSGREG4AHI2KG7ABW/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-07-12T08:47:08Z","links":{"resolver":"https://pith.science/pith/3JJY3DNXYFSGREG4AHI2KG7ABW","bundle":"https://pith.science/pith/3JJY3DNXYFSGREG4AHI2KG7ABW/bundle.json","state":"https://pith.science/pith/3JJY3DNXYFSGREG4AHI2KG7ABW/state.json","well_known_bundle":"https://pith.science/.well-known/pith/3JJY3DNXYFSGREG4AHI2KG7ABW/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2024:3JJY3DNXYFSGREG4AHI2KG7ABW","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"fff41535525e3ea669295937af001f3c8d4fb7d18159f69bd513026cefd5b307","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2024-08-30T16:28:29Z","title_canon_sha256":"59e589e5697516c0aa6a246e12849efb7fd4b9facfa7986581dc9353d8ad6f0e"},"schema_version":"1.0","source":{"id":"2408.17392","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2408.17392","created_at":"2026-07-05T09:01:14Z"},{"alias_kind":"arxiv_version","alias_value":"2408.17392v1","created_at":"2026-07-05T09:01:14Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2408.17392","created_at":"2026-07-05T09:01:14Z"},{"alias_kind":"pith_short_12","alias_value":"3JJY3DNXYFSG","created_at":"2026-07-05T09:01:14Z"},{"alias_kind":"pith_short_16","alias_value":"3JJY3DNXYFSGREG4","created_at":"2026-07-05T09:01:14Z"},{"alias_kind":"pith_short_8","alias_value":"3JJY3DNX","created_at":"2026-07-05T09:01:14Z"}],"graph_snapshots":[{"event_id":"sha256:584d0a67c7a8b0f15b03501ce4406fe417bbf5d50802d12cba5c8397917356de","target":"graph","created_at":"2026-07-05T09:01:14Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"integrity":{"available":true,"clean":true,"detectors_run":[],"endpoint":"/pith/2408.17392/integrity.json","findings":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938","summary":{"advisory":0,"by_detector":{},"critical":0,"informational":0}},"paper":{"abstract_excerpt":"The primary objective of Phase I oncology trials is to assess the safety and tolerability of novel therapeutics. Conventional dose escalation methods identify the maximum tolerated dose (MTD) based on dose-limiting toxicity (DLT). However, as cancer therapies have evolved from chemotherapy to targeted therapies, these traditional methods have become problematic. Many targeted therapies rarely produce DLT and are administered over multiple cycles, potentially resulting in the accumulation of lower-grade toxicities, which can lead to intolerance, such as dose reduction or interruption. To addres","authors_text":"Ying Yuan, Yunlong Yang","cross_cats":[],"headline":"","license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2024-08-30T16:28:29Z","title":"Dual-criterion Dose Finding Designs Based on Dose-Limiting Toxicity and Tolerability"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2408.17392","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:74adf5d478e147da4e8ea63b500f1dad53858fc1eceac180f5e8c1666c7ee980","target":"record","created_at":"2026-07-05T09:01:14Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"fff41535525e3ea669295937af001f3c8d4fb7d18159f69bd513026cefd5b307","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","primary_cat":"stat.ME","submitted_at":"2024-08-30T16:28:29Z","title_canon_sha256":"59e589e5697516c0aa6a246e12849efb7fd4b9facfa7986581dc9353d8ad6f0e"},"schema_version":"1.0","source":{"id":"2408.17392","kind":"arxiv","version":1}},"canonical_sha256":"da538d8db7c1646890dc01d1a51be00d911057d221d039b97682c6a34951b72c","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"da538d8db7c1646890dc01d1a51be00d911057d221d039b97682c6a34951b72c","first_computed_at":"2026-07-05T09:01:14.770281Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-07-05T09:01:14.770281Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"MswdP5WyqinALhugN40moC+fQ+IdA070hXZrKjtaJZTGIrasaBhiiFNGTzKE6Z2xEMaEIolB76LsN+Z+2KbLAA==","signature_status":"signed_v1","signed_at":"2026-07-05T09:01:14.770622Z","signed_message":"canonical_sha256_bytes"},"source_id":"2408.17392","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:74adf5d478e147da4e8ea63b500f1dad53858fc1eceac180f5e8c1666c7ee980","sha256:584d0a67c7a8b0f15b03501ce4406fe417bbf5d50802d12cba5c8397917356de"],"state_sha256":"58fca5114fe82731d375f1bdccce08c2b9791622367bd55e8e0517d7f03e7ce6"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"VoDNvY+Ad4bNTw7nvjOjS+fQ4J4rn5yb6nPeBM8v4vE35j8atu0PwrhfylTc77f+SKjfb7lOB/DAEKaKI/FUCQ==","signed_message":"bundle_sha256_bytes","signed_at":"2026-07-12T08:47:08.415183Z","bundle_sha256":"0c0e9ff994653fb1956588972e11a48446a3dcd41d333e7124d13b3876318570"}}